Quidel files for flu test clearance in the US:
This article was originally published in Clinica
Executive Summary
Quidel, of San Diego, California, has filed for FDA 510(k) clearance of its rapid, point-of-care test for influenza A and B. The test was developed with UK pharmaceutical company Glaxo Wellcome, which has a treatment for the virus (called Relenza) under review by the agency. Early diagnosis could help prevent the spread of the virus, which results in 300,000 admissions to US hospitals every year.